KA Stock Price, Chart, Stats & News

Kineta, Inc.
Save
7.05M
Market cap
–
Current P/E
–
Forward P/E
KA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 162.93% |
Operating margin | -100.09% |
Pretax margin | -117.01% |
Net margin | -117.43% |
Effective tax rate | -0.35% |
ROA | -604.99% |
ROE | 43.75% |
D/E | -0.05x |
Interest coverage ratio | -48.79x |
KA valuation
P/E | – |
P/S | 1.62x |
P/B | -0.56x |
P/CF | -2.72x |
P/FCF | -2.59x |
P/OCF | -2.72x |
PEG | -0.03x |
EV multiple | -1.14x |
About
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd.
Similar securities
Based on sector and market capitalization
Report issue











